arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU.
The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc.
Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.
Argentis Pharmaceuticals, LLC
1016 W. Poplar Ave., Suite 106-238 Collierville TN 38017 US
+1 (901) 881-8665
Copyright Argentis Pharmaceuticals, LLC.
All Rights Reserved.